Abstract:Despite the great achievements of immune checkpoint blockade (ICB) therapy on programmed cell death-1 (PD-1)/ programmed cell death-ligand 1 (PD-L1) axis, ICB monotherapy still faces obstacles in eradicating solid tumors due to the lack of tumor-associated antigens or tumor-specific cytotoxicity. Photothermal therapy (PTT) is a potential therapeutic modality because it can noninvasively kill tumor cells by thermal ablation and generate both tumor-specific cytotoxicity and immunogenicity, which holds great feasibility to improve the efficiency of ICB by providing complementary immunomodulation. Except for the PD-1/PD-L1 axis, the cluster of differentiation 47 (CD47)/signal regulatory protein alpha (SIRP alpha) pathway has been considered as a novel strategy of tumor cells to evade the surveillance of macrophages and inactivate the immune response of PD-L1 blockade therapy. Therefore, it is necessary to synergize the antitumor effect of dual-targeting PD-L1 and CD47. Although promising, the application of PD-L1/CD47 bispecific antibodies, especially in combination with PTT, remains a formidable problem, due to the low objective response, activity loss at relatively high temperature, or nonvisualization. Herein, instead of using antibodies, we use MK-8628 (MK) to down-regulate both PD-L1 and CD47 simultaneously through halting the active transcription of oncogene c-MYC, leading to elicitation of the immune response. The hollow polydopamine (HPDA) nanospheres are introduced as a biocompatible nanoplatform with high loading capacity and magnetic resonance imaging (MRI) ability to deliver MK and induce PTT (HPDA@MK). Compared to preinjection, HPDA@MK exhibits the strongest MRI signal at 6 h postintravenous injection to guide the precise combined treatment time. However, due to the local delivery and controlled release of inhibitors, HPDA@MK down-regulates c-MYC/PD-L1/CD47, promotes the activation and recruitment of cytotoxic T cells, regulates the M2 macrophages polarization in tumor sites, and especially boosts the combined therapeutic efficacy. Collectively, our work presents a simple but distinctive approach for c-MYC/PD-L1/CD47-targeted immunotherapy combined with PTT that may provide a desirable and feasible strategy for the treatment of other clinical solid tumors.

HDAC6 Inhibitor Loaded Bimetallene Nanosheets with Antagonizing Thermoresistance for Augmented Mild Photothermal Therapy

Hsp90 Inhibitor-Loaded IR780 Micelles for Mitochondria-Targeted Mild-Temperature Photothermal Therapy in Xenograft Models of Human Breast Cancer

Hyaluronic Acid-Functionalized Polydopamine Nanoparticles Augment Photothermal Therapy via Synergetic Tumor-Targeting and Heat Shock Protein Inhibition

A NIR-Activated and Mild-Temperature-Sensitive Nanoplatform with an HSP90 Inhibitor for Combinatory Chemotherapy and Mild Photothermal Therapy in Cancel Cells

?Electron Transport Chain Interference? Strategy of Amplified Mild- Photothermal Therapy and Defect-Engineered Multi-Enzymatic Activities for Synergistic Tumor-Personalized Suppression

Self-Delivery Nanomedicines Reverse Thermal Resistance to Enhance Tumor Mild-Temperature Photothermal Therapy

Biomimetic nanoparticles for effective mild temperature photothermal therapy and multimodal imaging

A Diketopyrrolopyrrole-Based All-in-One Nanoplatform for Self-Reinforcing Mild Photothermal Therapy Cascade Immunotherapy for Tumors

Simultaneous Inhibition of Heat Shock Response and Autophagy with Bimetallic Mesoporous Nanoparticles to Enhance Mild‐Temperature Photothermal Therapy

Blockage of HSP90 and IDO1 Pathway by Α-Msh Modified Nanoelicitor to Dual-Facilitate Mild Photothermal Therapy

Hemoglobin-Decorated Boron-Carbon Nanosheets with Catalytic Ability and Near-Infrared II Light Response for Tumor Photothermal-Chemodynamic Therapy

NIR-controlled HSP90 Inhibitor Release from Hollow Mesoporous Nanocarbon for Synergistic Tumor Photothermal Therapy Guided by Photoacoustic Imaging

Mutually Synergistic Nanoparticles for Effective Thermo‐Molecularly Targeted Therapy

DNAzyme-adsorbed Polydopamine@mno2 Core-Shell Nanocomposites for Enhanced Photothermal Therapy Via the Self-Activated Suppression of Heat Shock Protein 70.

Molecular Targeting-Mediated Mild-Temperature Photothermal Therapy with a Smart Albumin-Based Nanodrug.

Versatile Biomimetic Cantharidin-Tellurium Nanoparticles Enhance Photothermal Therapy by Inhibiting the Heat Shock Response for Combined Tumor Therapy

NIR-triggered dual sensitization of nanoparticles for mild tumor phototherapy

Lysosomal Activable Vorinostat Carrier-Prodrug Self-Assembling with BPQDs Enables Photothermal Oncotherapy to Reverse Tumor Thermotolerance and Metastasis.

Reversing Immune Suppression and Potentiating Photothermal Immunotherapy Via Bispecific Immune Checkpoint Inhibitor Loaded Hollow Polydopamine Nanospheres

Cancer Cytomembrane-Cloaked Prussian Blue Nanoparticles Enhance the Efficacy of Mild-Temperature Photothermal Therapy by Disrupting Mitochondrial Functions of Cancer Cells

Black Phosphorus Nanosheets for Mild Hyperthermia-Enhanced Chemotherapy and Chemo-Photothermal Combination Therapy